Once-daily combinations of a basal insulin with a GLP-1 RA offer two agents with complementary mechanisms of action for better glycemic control in type 2 diabetes mellitus, while reducing the risks of hypoglycemia and weight gain, and allowing for simplification of the treatment regimen. The DUAL and DUAL VII studies have demonstrated the benefits of a fixed ratio combination of insulin degludec and liraglutide in patients uncontrolled on basal insulin.
Stewart Harris, MD, MPH, FCFP, FACPM
Sonja Reichert, MD, MSc, CCFP
Amanda Mikalachki, BScN, Certified Diabetes Educator
- Learning Objective #1
- Learning Objective #2